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Abstract
Mucoadhesive nanostructured systems comprising poloxamer 407 and Carbopol 974P® have already demonstrated good mucoad-
hesion, as well as improved mechanical and rheological properties. Curcumin displays excellent biological activity, mainly in oral
squamous cancer; however, its physicochemical characteristics hinder its application. Therefore, the aim of this study was to
develop nanostructured formulations containing curcumin for oral cancer therapy. The photophysical interactions between
curcumin and the formulations were elucidated by incorporation kinetics and location studies. They revealed that the drug was
quickly incorporated and located in the hydrophobic portion of nanometer-sized polymeric micelles. Moreover, the systems
displayed plastic behavior with rheopexy characteristics at 37 °C, viscoelastic properties and a gelation temperature of 36 °C, which
ensures increased retention after application in the oral cavity. The mucoadhesion results confirmed the previous findings with the
nanostructured systems showing a residence time of 20 min in porcine oral mucosa under flow system conditions. Curcumin was
released after 8 h and could permeate through the porcine oral mucosa. Cytotoxicity testing revealed that the formulations were
selective to cancer cells over healthy cells. Therefore, these systems could improve the physicochemical characteristics of curcumin
by providing improved release and permeation, while selectivity targeting cancer cells.
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Introduction
The development of nanostructured systems containing polox-
amer 407 (P407) and Carbopol 974P® (C974P) have previ-
ously been shown to have rheological and mechanical charac-
teristics beneficial for pharmaceutical and biomedical use [1].
P407 is a non-ionic block copolymer with polypropylene oxide
(PPO) and polyethylene oxide (PEO) segments, which can
display thermoresponsive properties forming nanometer-sized
micelles, hydrogels and lyotropic liquid crystals [2,3]. The
increase of temperature can promote the self-assembly from
unimers to micelles, with large endothermic heat. In this sense,
PPO-groups dehydrate in a hydrophobic core with a surround-
ing hydrated shell. Higher concentrations of P407 are used
(15% to 20%, w/w) as colloidal gelling systems in a cubic hex-
agonal core with ordered structure, which enable the solubiliza-
tion of hydrophilic and hydrophobic drugs [4-9]. Moreover,
C974P is an acrylic-acid derivative, highly cross-linked, hydro-
philic, and displays mucoadhesive properties [1]. In this sense,
an increase in temperature promotes the nanometer-sized
assembly into three-dimensional micelles with a hydrophobic
core of PPO and a hydrophilic shell of PEO that can interact by
hydrogen bonds with the hydrophilic acrylic-acid derivative
polymer. This results in a binary polymeric system with good
viscoelasticity, mucoadhesion, softness and flow properties
[1,10,11]. Therefore, different combinations and the characteri-
zation of their different functionalities have been reported in the
literature [1-3]. These nanostructured systems with mucoadhe-
sive and thermoresponsive properties could provide new prop-
erties, including biocompatibility, improved mechanical charac-
teristics tailored for the specific application, in addition to new
release mechanisms and improved permeability [9,12-14].
The delivery through the mucosa via buccal administration has
shown several advantages as a drug delivery target site. The
ease of accessibility for administration and removal, more
permeable than skin and containing a rich blood flow and
avoidance of first-pass effects, makes this route useful for
systemic or local applications [15]. However, the dynamic
physiological properties of the oral cavity, such as the variable
salivary flow due to different types of stimulation, during masti-
cation, speech and swallowing, could hinder the development of
drug delivery systems for this route [15,16]. In order to avoid
these drawbacks, nanostructured systems with mucoadhesive
polymers, such as acrylic-acid derivatives, have been investigat-
ed due to some important characteristics. They can provide inti-
mate contact between the dosage form and tissue, which could
guarantee high drug flux through the absorbing tissue to subse-
quently increase drug permeation and bioavailability [14,15]. In
addition, the incorporation of thermoresponsive materials, like
P407, could facilitate the administration and preparation of
these formulations [10,17].
Head and neck cancer is the sixth most common malignancy
worldwide and the prognosis is poor, with a five-year survival
of less than 54% and accounting for around 300,000 deaths and
more than 550,000 new cases each year worldwide [18,19].
Oral squamous cell carcinoma (OSCC), the primary cause of
this cancer type, has been associated with many risk factors,
mainly related to excessive intake of alcoholic beverages,
tobacco use, high exposure to UV radiation, immunosuppres-
sion and age. These risk factors are involved in the transformat-
ion of healthy oral mucosal cells (called keratinocytes) to
premalignant dysplastic lesions, which can develop to OSCC.
Although these lesions can develop in different regions of the
oral cavity, including the lip, buccal mucosa, and hard and soft
palate, they are most commonly found on the tongue and floor
of the mouth [18,20-24]. Despite the advances in conventional
methods (chemotherapy, radiotherapy and surgery), the prog-
nosis of OSCC has not improved. In addition, many adverse
effects and complications have been reported with current treat-
ment strategies including, facial disfigurement, loss of speech,
mastication and swallowing and even in the mildest cases oral
mucositis and candidiasis, which drastically reduce the life
quality of the patient [21,25]. Early diagnosis by a dentist or
physician ensures early treatment to avoid metastatic spread
[26-28].
Curcuminoids, derived from curcuma root (Curcuma longa),
have been used for many centuries in Asian countries as a spice
and coloring agent, but also as a medicine [29]. This group of
yellow polyphenols are composed of curcumin (CUR), deme-
toxycurcumin and bis-demetoxycurcumin, which represent
77%, 17% and 3% of the content of the dried extract from
curcuma root, respectively [30,31]. CUR has shown anti-in-
flammatory, antirheumatic and antioxidant activities and it has
been used in hepatic and other chronic diseases including diabe-
tes [32]. Recently, the activity of CUR as an anticancer drug has
been evidenced and shown to act on a variety of molecular
targets that regulate the proliferation and apoptosis, decrease the
expression of NF-κB and increase insulin-like growth factor-
binding protein 5 (IGFBP-5) and cytochrome P450, family 1,
member A1 (CYP1A1) [32-34]. Moreover, CUR can be useful
as adjuvant in cancer treatment, after surgical procedure, or in
combination with chemotherapy [35-41]. Despite its broad ther-
apeutic potential, CUR has limited stability to light and pH, as
well as poor solubility. CUR is also susceptible to degradation
due to the formation of phenylate anions and high production of
CUR radicals, since this polyphenol has demonstrated high
lipophilicity (log P 3.29) and low solubility in aqueous solu-
tions and under alkaline conditions (pH > 7) [30,31,42]. These
physicochemical characteristics hinder the bioavailability and
therapeutic efficacy of this drug. Consequently, there is a need
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Table 1: Anisotropy (r) of formulation containing poloxamer 407 (P407), Carbopol 974P(C974P) and curcumin (CUR) under different conditions of pH
and temperature.
Formulation r
37 °C (pH 5) 37 °C (pH 7) 45 °C (pH 7) 37 °C (pH 10)
P407/C974P/ CUR 0.2104 0.2517 0.2881 0.2863
to associate CUR with carriers to ensure the delivery to the
target site and thereby protect the drug from degradation,
increase the solubility and provide controlled release as well as
permeation, while maintaining biological activity [31,43-45].
To our knowledge, systems containing P407 and C974P have
not been investigated to carry CUR and therefore the aim of this
study was to develop nanostructured systems containing P407,
C974P and CUR to target OSCC. Once developed, we investi-
gated the behavior of the drug in the formulations for their
chemical, rheological, mechanical and mucoadhesive character-
istics. We also measured the in vitro drug release profile,
permeation and the cytotoxic potential of these systems.
Results and Discussion
Interaction studies of curcumin in
mucoadhesive nanostructured systems
As CUR is highly hydrophobic, unstable and susceptible to deg-
radation by light and pH [31], the interaction of CUR formula-
tions was studied by photophysical methods. The aim was to
understand the interaction between this hydrophobic drug with
the hydrophobic core of the three-dimensional structure of
P407-micelles.
Investigation of CUR interaction with the system
In order to improve the understanding of these interactions be-
tween CUR and the formulations, stability assays using photo-
physical studies were performed to provide information about
the interactions of CUR with the polymer blends under differ-
ent conditions, including the cool storage temperature in refrig-
erator (10 °C), administration temperature of the formulation to
the patient (25 °C), body temperature (37 °C) and over body
temperature (45 °C) at pH 7, but also at pH 5 and 10 at 37 °C
[46]. The formulations composed of P407, C974P and CUR
showed pH 5 during the preparation and before the pH adjust-
ment step, due to the acidic properties of the mucoadhesive
polymers [47]. Furthermore, the stability by photophysical
studies of polymer blends containing 0.01% (w/w) P407,
1.6 × 10−4% (w/w) C974P and 1.8 × 10−5 mol/L CUR were
spectroscopically evaluated using an emission slit of 5–10 nm.
The spectra are displayed in Figure 1. The systems showed a
higher emission intensity and larger widths at pH 7, due to the
thermal energy employed for CUR encapsulation during the
rotary evaporation.
Figure 1: Emission spectra of systems containing 0.01% (w/w) P407,
1.6 × 10−4% (w/w) C974P and 1.8 × 10−5 mol/L CUR at 10 °C, 25 °C,
37 °C, 45 °C in pH 7, 37 °C in pH 5 and pH 10, obtained with an
emission slit of 5–10 nm.
Moreover, the emission intensity of the formulations was lower
at pH 10 in comparison to pH 7 at 37 °C. These results could be
explained by new chemical species from pKa that do not appear
in the emission spectra due to the excitation wavelength of
422 nm (CUR maximum absorption).
Anisotropy of fluorescence (r) was also investigated for the
samples with maximum peak spectral emission (Table 1).
Anisotropy is considered a powerful technique to investigate
the molecular dynamics of fluorescent solutes, such as CUR.
During the fluorescence analysis, the molecules are excited by
linearly polarized light, and they absorb and emit the fluores-
cence in a polarized way. If the emission is highly polarized
(approximately or equal to one), the molecules will not rotate
between absorption and emission, which would suggest that
they are associated with macromolecules. Therefore, the emis-
sion of polarization is described as anisotropy [48,49]. Further-
more, this measurement can be used to characterize specific or
nonspecific linking as it is dependent on the fraction of fluores-
cent solute interacting with macromolecules or on the rigidity of
the formed complex [48]. Anisotropy values close to zero are
related to depolarized emission and intense molecule rotation
[49].
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Figure 2: Incorporation kinetic profiles of systems containing poloxamer 407 (P407), Carbopol 974P (C974P) and curcumin (CUR) obtained at 25 °C
and 37 °C.
Furthermore, the temperature changes were more remarkable
than the variation in pH, with the systems investigated at 45 °C
displaying higher anisotropy values in comparison to those
evaluated at 37 °C.
Incorporation kinetics
Incorporation kinetics were evaluated by observing the fluores-
cence emission properties of CUR in order to evaluate if the
spectra obtained from the thermal analysis were influenced by
the end time of the sample preparation. The time required for
CUR incorporation into the polymeric micelles was also deter-
mined. Moreover, this analysis allows for the understanding of
diffusion and interaction of CUR at a micellar interface. The
analyses were carried out in a fluorescence spectrometer with
emission and excitation slits of 5–10 nm at 25 °C, once the
polymeric micelles were formed, to ensure higher specificity of
the results [4]. This evaluation simulates the incorporation of
CUR into polymeric systems by the second method of prepara-
tion, since the binary polymeric system was prepared and then
CUR was incorporated, without pH adjustment at pH 5. On the
other hand, by the first method of preparation, the incorpora-
tion of CUR was performed during the evaporation of ethanol
in the rotary evaporator. Therefore, the incorporation kinetic
profile was carried out at 25 and 37 °C, for simulation of the
temperature of CUR incorporation by the second and the first
preparation method, respectively. Furthermore, the analysis at
37 °C results in the condition where P407 micelles are well-
structured. The profiles and kinetic adjustments of CUR incor-
poration into the polymeric systems is shown in Figure 2.
In general, the effect of temperature did not change the pattern
of CUR incorporation. The emission intensity displayed an
initial peak with further decrease and maintained emission until
the end of the analysis, which hampered the generation of a
kinetic pattern for first or second order in both analyzed temper-
atures. These mechanisms would improve the understanding of
the involved mechanisms of this interaction. Kinetic studies of
CUR and P407 were carried out by Braga [50], and the initial
peak was not observed. Thus, the existence of this initial peak
(pattern I) is suggested to occur due to the reorganization of the
nanostructured system when CUR is quickly incorporated, as
well as the presence of C974P in the micelle structure and
subsequent redistribution of CUR in the micellar interface in
order to ensure the same concentration of the molecule in the
polymeric micelles. Moreover, CUR is incorporated from a
highly concentrated medium (ethanolic stock solution) to a low
concentrated medium (binary polymeric systems), where a
partitioning process take place in a dynamic exchange between
CUR molecules incorporated in the micelle and those dissolved
in the ethanol until the equilibrium is achieved with decrease in
the emission intensity [51]. Two distinct stages (pattern II and
III) after pattern I could be observed due to the stabilization of
these micellar systems, where CUR becomes aggregated with
lower emission intensity.
The temperature was found to influence the velocity of CUR in-
corporation. This micellar system at 25 °C showed fast incorpo-
ration in different locations, at around 1 min, due to the facili-
tated accessibility of CUR in the monomeric aggregates of P407
and C974P. In addition, lower intensity emission peaks could be
observed for these systems at 25 °C, since at lower tempera-
tures PPO groups are hydrated and display weak hydrophobic
interactions [6]. On the other hand, the systems evaluated at
37 °C demonstrated slower incorporation, around 60 min, due
Beilstein J. Nanotechnol. 2019, 10, 2304–2328.
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Figure 3: Fluorescence emission spectra and Ksv determination by Equation 3 of CUR (3.6 × 10−5 mol/L) at 25 °C (A and B) and 37 °C (C and D) for
P407 (0.2%, w/w) and C974P (3.2 × 10−4%, w/w); λexc = 422 nm with a 5–10 nm slit width. The spectral variation of CUR with I− concentration as de-
termined by fluorescence emission at 25 °C (B) and 37 °C (D). The arrows in (A) and (C) indicate the fluorescence suppression direction of CUR with
I− concentration.
to the structuring of the micelles to promote a steric hindrance
as well as higher emission intensity that promotes increased
hydrophobicity of PPO blocks with higher affinity with CUR.
CUR localization by fluorescence quenching
The localization of CUR in the polymeric systems was per-
formed by fluorescence quenching, using iodide as a hydro-
soluble suppressor [2,52-54]. The studies were performed at
25 °C (room and administration temperature) and 37 °C (body
temperature). Using this assay, it is possible to evaluate the
location of CUR in the polymeric system during drug release
and to determine the location of encapsulated drugs. If the drug
is located in an external location, it forms a complex with
iodide, and consequently, the intensity of the spectra decreases
[52]. The fluorescence quenching studies were carried out with
formulations composed of 0.02% (w/w) P407, 3.2 × 10−4%
(w/w) C974P and 3.6 × 10−5 mol/L CUR prepared by solid
dispersion and stored at 25 °C (Figure 3). Considering the high
concentration of water, this analysis was not influenced by the
viscosity of the formulations. Moreover, the system was con-
stantly agitated with a magnetic stir bar.
In the spectra shown in Figure 3, it was evident that formula-
tions evaluated at 37 °C showed a higher spectral intensity in
comparison to studies performed at 25 °C. These results can be
explained by the structure of thermoresponsive systems in
response to an increase in temperature. Moreover, for the
formulations evaluated at 25 °C, a decrease in emission was ob-
served during iodide addition, which demonstrates the higher
accessibility of the hydro-soluble suppressor, and consequently,
higher collisions with CUR [52,54,55]. However, the spectra of
the systems evaluated at 37 °C exhibited overlapping peaks,
which demonstrates that CUR is not accessible to complex with
the hydro-soluble suppressor. This suggests that the CUR is
localized in the micelle core at 37 °C, which results in a slower
release from the nanostructured system.
Beilstein J. Nanotechnol. 2019, 10, 2304–2328.
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Figure 4: SEM micrographs of systems containing 15% (w/w) P407, 0.25% (w/w) C974P: without CUR original magnification ×1500 (A, scale bar =
100 µm) and ×4000 (B, scale bar = 40 µm); containing CUR original magnification ×1800 (C, scale bar = 50 µm) and ×5000 (D, scale bar = 30 µm).
High Stern–Volmer constant (Ksv) values are correlated with
the CUR being externally located, with accessibility for
complexation with iodide. Conversely, low Ksv values
suggest an internal location, and consequently, no accessibility
to the suppressor molecule. The system evaluated at 37 °C
displayed lower Ksv values (Ksv = 1.3403 mol/L), whereas
formulations evaluated at 25 °C showed higher Ksv values
(Ksv = 5.8090 mol/L).
In this context, systems containing C974P displayed spectros-
copic characteristics that favored further studies, as they
presented lower Ksv values, indicating internal location of CUR
in P407-micelles as well as higher anisotropy values. This result
suggested that the viscosity of the microenvironment helped to
obtain stronger interactions. In addition, the system stored at
25 °C also showed interesting results, in that they did not show
any visible sign of CUR precipitates after 15 days of storage
(Figure S1 in Supporting Information File 1), indicating that
CUR was in an internal location.
Morphological analysis by scanning electron
microscopy
The morphological characteristics of the preparations with and
without CUR were evaluated by scanning electron microscopy
(SEM) (Figure 4). Micrographs of formulations containing
P407 and C974P revealed polymeric fragments with heterogen-
eous, but well defined, structures. This was probably due to the
presence and movement of water that was removed due to
the freeze-drying process. Besides, the portion of the micro-
structures or microchannels exhibiting exposed breakage
(Figure 4B) were probably due to the interaction between P407
and C974P.
SEM micrographs of preparation containing CUR showed the
presence of more irregular structures and channels without
defined orientation. These data can be explained by the prepara-
tion method since the samples were frozen at −20 °C, where
restructuring of the polymer can be observed. Moreover, the
negative charge of C974P and CUR hindered the exploration of
the structure at higher magnification due to the interaction of
these components and the microscopic filaments.
Morphological analysis by transmission electron
microscopy
The nanostructured organization of the polymeric systems is ev-
idenced in Figure 5. In the absence of CUR, the micelles
(Figure 5A and 5B) are represented by the white spherical
shapes of approximately 20 nm in diameter. Some authors have
performed transmission electron microscopy (TEM) of P407-
systems and showed smaller micelles (≈10 nm) with higher
homogeneity [56-58].
These differences in the micelle size could be due to the pres-
ence of C974P and interactions between PEO segments of P407
and hydroxyls of C974P.
Moreover, the TEM images of the nanostructured systems con-
taining CUR have been obtained at 37 °C (Figure 5C and 5D).
Beilstein J. Nanotechnol. 2019, 10, 2304–2328.
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Figure 5: TEM images of nanostructured systems at 37 °C demonstrating the individual micellar organization: (A) and (B) represent the nanostruc-
tured systems in the absence of CUR, scale bar equals to 200 and 100 nm, respectively. (C) and (D) represent the nanostructured systems contain-
ing CUR, scale bar equals to 200 and 100 nm, respectively.
Considering that CUR is found in the hydrophobic PPO core, as
demonstrated in the localization studies, it was observed to have
better homogenization of the size and shape of the micelles in
comparison to the systems without the drug. Additionally, the
micelles were larger (≈40 nm), probably due to the interaction
of PPO and CUR. In this sense, the presence of CUR promoted
a better structuring of the system.
Micelle size analysis
The micelle size, polydispersity index (PDI) and D90% of the
nanostructured systems with and without CUR were deter-
mined by dynamic light scattering (DLS) and the results are
displayed in Table 2.
The polymer concentration should be low enough to circum-
vent multiple scattering in DLS measurements [56]. Thus, the
systems were diluted in two different concentrations, 0.3% and
1.5% (w/w), in relationship to the amount of P407 in the formu-
lations. It was observed that the system is quite dynamic. Thus,
the most diluted system (0.3%, w/w) showed a significantly
higher micelle size and PDI (p < 0.05), probably due to the
presence of water, which can enable higher hydration of the
polymeric chains. The presence of CUR significantly reduced
the PDI (p < 0.05) for the system diluted at 0.3% (w/w) P407 at
both temperatures, and at 37 °C for the system diluted at 1.5%
(w/w) P407. Moreover, the presence of CUR did not change the
PDI for the different P407 dilutions (0.3 and 1.5%, w/w) at
37 °C. The presence of CUR decreased the micelle size (D) in
the 0.3% (w/w) P407 dilution at 25 °C, but significantly in-
creased D for all other conditions of (p < 0.05). Thus, the
increase in the P407 concentration results in nanometer-sized
micelles with a lower PDI. In addition, the presence of CUR in-
creases the micelle size and also results in a low PDI. The TEM
results and particle size when diluted to 0.3% (w/w) P407 were
Beilstein J. Nanotechnol. 2019, 10, 2304–2328.
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Table 2: Micelle size (D), polydispersion index (PDI) and micelle size distribution (D10%, D50% and D90%) of the nanostructured systems with and
without CUR, evaluated at 25 °C and 37 °Ca.
System dilution (%, w/w)b Analysis Temperature
25 °C 37 °C
P407/C974P P407/C974P/CUR P407/C974P P407/C974P/CUR
0.3 D (nm) 26.87 ± 5.37 12.83 ± 0.12 14.50 ± 6.32 19.23 ± 0.06
PDI 1.04 ± 0.04 0.39 ± 0.02 0.24 ± 0.02 0.23 ± 0.01
D10% (nm) 21.70 ± 0.00 10.77 ± 0.06 10.97 ± 0.31 15.50 ± 0.17
D50% (nm) 21.87 ± 0.70 11.77 ± 0.06 13.23 ± 0.76 18.17 ± 0.12
D90% (nm) 25.57 ± 3.39 15.47 ± 0.15 18.20 ± 1.21 22.30 ± 0.10
1.5 D (nm) 5.10 ± 0.17 15.90 ± 1.31 13.50 ± 0.35 11.33 ± 0.64
PDI 0.29 ± 0.01 0.17 ± 0.00 0.14 ± 0.02 0.19 ± 0.01
D10% (nm) 3.73 ± 0.15 11.53 ± 1.06 9.83 ± 0.21 8.37 ± 0.42
D50% (nm) 4.57 ± 0.21 14.00 ± 1.28 12.13 ± 0.38 10.20 ± 0.44
D90% (nm) 6.30 ± 0.26 20.20 ± 1.67 17.03 ± 0.47 14.50 ± 0.53
aResults represents the average of at least three replicate analyses. bIn relationship to P407 amount in the formulation.
similar (but not the same) due to water removal during the sam-
ple preparation for TEM analysis [56]. Therefore, the results
showed the nanometer-sized structuring of the systems.
Rheology
The flow properties of binary polymeric systems containing
15% (w/w) P407, 0.25% (w/w) C974P, 0.08% (w/w) CUR were
evaluated at 25 and 37 °C (Figure 6).
The nonlinear behavior to shear stress due to the shear rate
(non-Newtonian), resulting in structural changes, was main-
tained even after the incorporation of CUR in the polymer
blends. Moreover, the addition of CUR in binary polymeric
systems did not lead to a change in flow rheological profiles at
25 °C, whereas a slight decrease of shear stress was observed
for systems evaluated at 37 °C. In this way, CUR did not
change the structuring of the system. Conversely, the increase
in temperature leads to an increase in shear stress due to the
thermoresponsive properties of the preparations.
Low hysteresis areas and different yield values could be ob-
served in a prominent way at 37 °C, in comparison to systems
investigated at 25 °C. Consequently, these systems showed
shear thinning behavior flow, which is considered to be a desir-
able characteristic for pharmaceutical semi-solid formulations
in order to facilitate clinical administration in a uniform way
over the mucous tissue of the buccal cavity. Subsequently, it
can recover the rheological properties that these systems
presented before the shear stress application [10,59,60].
The effect of the presence of CUR and the increase in tempera-
ture were statistically evaluated by the consistency index (K),
flow behavior index (n) and yield value. These indexes were
calculated by the rheological models, Ostwald de Waele,
Casson and Herschel–Bulkley. In order to verify the rheologi-
cal model that could properly fit the K and n value, R or Χ2
were calculated and it was observed that R values were closer to
1, according to Herschel–Bulkley theory (Table 3).
The presence of CUR did not lead to any significant differ-
ences (p = 0.6875) in the consistency index (K) of the prepara-
tions, and the formulations kept the same resistance to deforma-
tion [11], confirming that CUR is located in the core of the
polymeric micelle (as shown by the localization analysis) and
therefore did not alter the interactions between P407 and C974P
in order to change the viscosity. Otherwise, the increase in tem-
perature led to the significant increase of K (p = 0.000210) due
to the thermoresponsive properties of P407 [4].
The formulations with and without CUR showed shear thinning
behavior due to n values lower than 1 (Table 2). The positive
yield values demonstrated that these systems are plastic [9].
Thus, the increase in temperature significantly decreased the n
values (p < 0.05), whereas the presence of CUR had no signifi-
cant influence on the n values (p = 0.138912).
The yield value and hysteresis area results are shown in
Table 2. The yield value demonstrates the ability of the formu-
lations to withstand a significant shear stress without flow, and
then after the weakening of the structure, the ability to start to
flow [61]. Both an increase in temperature and incorporation of
CUR led to significant differences (p < 0.05) in the yield value.
The significant increase in yield value with an increase in tem-
perature and subsequent micelle structuring can be explained by
Beilstein J. Nanotechnol. 2019, 10, 2304–2328.
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Figure 6: Flow rheograms of formulations containing 15% (w/w) P407, 0.25% (w/w) C974P (∆ - green) and 15% (w/w) P407, 0.25% (w/w) C974P and
0.08% (w/w) CUR (◊ - blue). The closed symbols represent up-curve and open symbols represent down-curve. Error bars have been omitted for
clarity, and each rheogram represents the average of at least three replicates with variation coefficient 10%.
Table 3: Consistency index (K), flow behavior index (n), yield value and hysteresis area at 25 and 37 °C for systems containing P407, C974P with
and without CUR.
Rheological properties Temperature (°C) P407/C974P/CUR (%, w/w)
(15/0.25/0) (15/0.25/0.08)
K (Pa·s)n a 25 5.4027 ± 0.2110 6.1910 ± 0.6374
37 15.8867 ± 0.7379 15.4367 ± 0.8164
n (dimensionless)a 25 0.6311 ± 0.0058 0.6094 ± 0.0130
37 0.5371 ± 0.0030 0.5395 ± 0.0068
Yield value (Pa)a 25 7.7960 ± 0.4634 2.2065 ± 0.8565
37 48.6033 ± 3.0647 26.4000 ± 0.5200
Hysteresis area (Pa/s)a,b 25 7036.80 ± 2423.70 14381.16 ± 3607.37
37 −17520.00 ± 8553.99 −26805.00 ± 2725.00
aEach number represents the mean of at least three replicates; bPositive number represents rheopexy and negative numbers represent thixotropy.
the transition from liquid to gel. However, the increase of
CUR led to a significant decrease in the yield value, probably
due to the higher exposure of the hydrophilic portion to water
[62,63].
The hysteresis area of the formulations was investigated by
RheoWin 4.10.0000 software (Haake®). The formulations
displayed thixotropic behavior at 25 °C, which provides resis-
tance to breakage in addition to higher structural flexibility,
Beilstein J. Nanotechnol. 2019, 10, 2304–2328.
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Figure 7: (A) Elastic modulus, G’ (Pa), (B) viscous modulus, G” (Pa), (C) dynamic viscosity, η’ (Pa), and (D) tan δ of the formulations containing P407
(15%, w/w) and C974P (0.25%, w/w) with and without CUR (0.08%, w/w) evaluated at 25 and 37 °C. Each point represents the average of at least
three replicates with a variation coefficient lower than 10%.
which is due to the lower viscosity after the application of shear
stress [64,65]. Conversely, the formulations exhibited a signifi-
cant decrease (p < 0.05) in the hysteresis area at 37 °C (Tukey).
Thus, both formulations (with and without CUR) demonstrated
rheopetic behavior due to the higher influence of P407 in the
structuring of the system at 37 °C. This behavior is considered
important in order to increase the retention of preparations in
the buccal cavity [59,60]. Moreover, the presence of CUR sig-
nificantly decreased the hysteresis area (p < 0.05) at 37 °C.
These systems displayed rheopexy at 37 °C, which are negative
values. In this sense, the decrease in the hysteresis area means
that the systems showed higher rheopexy areas. The presence of
CUR resulted in an increase in the micelle size and homo-
geneity, as evidenced by TEM and the size analysis. Thus, an
improved organization and higher resistance to the stress and
shear rate applied were observed. This higher resistance to the
flow explains the higher rheopexy of the systems containing
CUR, mainly at 37 °C.
The effects of the presence of CUR and the change in tempera-
ture on the viscoelastic properties (G’, G”, η’ and tan δ) of the
systems was also evaluated (Figure 7).
An increase in frequency for both the elastic and viscous
modulus was observed (Figure 6A and 6B). A decrease in the
dynamic viscosity and loss tangent were observed with increas-
ing frequency (Figure 6C and 6D). The exception is for the loss
tangent of the CUR systems evaluated at 25 °C, which remain
constant at the majority of the frequencies. Moreover, the
increase in temperature led to the increase of G’, G”, η’ and a
decrease in tan δ for formulations with and without CUR. This
behavior has already been previously observed for systems con-
taining P407 and other acrylic acid derivatives [9,11], as well as
polymer blends containing P407 and C974P or PCB [1,10].
Regarding the effect of the presence of CUR at 25 °C, an
increase of G’, G” and η’ and a decrease of tan δ was observed
for most frequencies. Hence, these changes provided better
structuring and elasticity at 25 °C. However, polymer blends
containing CUR investigated at 37 °C displayed lower G’, G”
and η’ with an absence of significant changes for tan δ. These
results could be explained by the difficult micelle structuring of
P407 and jellified three-dimensional chains.
Furthermore, both preparations exhibited viscoelastic behavior,
except for the polymer blends containing P407 and C974P with-
out CUR at 25 °C. In these formulations, the G’ values
exceeded G” and the loss tangent was smaller than 1 for the
viscoelastic preparations. Thus, the viscoelasticity is favorable
to oscillatory movements performed at 25 °C, occurring during
transport and storage of formulations [9].
The gelation temperature, Tsol–gel, of the formulations with and
without CUR was investigated as well. The systems displayed
lower G’ values at low temperatures; however, high G” values
were observed as the temperature was increased. Even with
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Figure 8: Textural properties of the systems containing P407, C974P and CUR, investigated at 25 and 37 °C: (A) hardness, (B) compressibility,
(C) adhesiveness, (D) elasticity and (E) cohesiveness. Each value represents at least three replicates.
the incorporation of CUR, the dynamic viscosity increased
significantly due to the increase in temperature and gelation
temperature [59,66]. The presence of CUR significantly in-
creased (p < 0.05) the gelation temperature of the preparations
from 36.03 ± 0.06 °C in systems without CUR (15/0.25) to
36.94 ± 0.12 °C in systems with CUR (15/0.25/0.08). Conse-
quently, the structuring of the jellified three-dimensional chain
is explained by the difficulty of the externalization of the hydro-
philic portion (i.e., ethylene oxide (EO)) of micelles to interact
with water and initiate the interaction between EO and C974P-
hydroxil [43]. Despite the significant increase in the gelation
temperature of the formulations containing CUR, the Tsol–gel is
considered suitable (between 25 and 37 °C).
Texture profile analysis
The mechanical properties of the preparations with and without
CUR were evaluated by texture profile analysis (TPA). The
information about the physical structure of gels obtained by
TPA are useful for the development of nanostructured mucoad-
hesive systems related to the preparation, packaging, adminis-
tration and structuring from development until the application
and performance evaluation at the application site. In this way,
the formulations should be resistant to the forces applied by the
environment. This is also true for saliva, which can also be
considered as a natural protection in the organism against impu-
rities exposed to the mucosa and can hinder the retention of
such systems and thereby impair the clinical efficacy [65-67].
Hardness, compressibility, adhesiveness, elasticity and cohe-
siveness results for the formulations with or without CUR at 25
and 37 °C are given in Figure 8. In addition, the effects of the
presence of CUR and the increase in temperature were statisti-
cally evaluated for each parameter.
Hardness is an indicator of the ability to remove the formula-
tion from the packaging material and its subsequent spread-
ability on the mucous tissue in a uniform layer to avoid any
discomfort to the patient. Conversely, compressibility expresses
the application of the formulation in the buccal cavity. Low
compressibility and hardness values are desirable in order to
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facilitate the removal of the preparation from the packaging ma-
terial and administration in the buccal cavity and topically
applied over the mucosa [66-68]. However, formulations should
display enough resistance to avoid the product flowing from the
packaging material and application site [10]. Adhesiveness,
considered as the required work necessary to overcome the
attraction forces between the sample surface and the polycar-
bonate probe surface, is a desirable parameter for mucoadhe-
sive preparations aimed at buccal applications. In this sense, a
higher adhesion could implicate higher retention, and conse-
quently, higher clinical efficacy of preparations for buccal drug
[67,68].
The incorporation of CUR significantly decreased (p < 0.05) the
hardness and compressibility, which is a desirable character-
istic to facilitate application of the formulation in the buccal
cavity. This behavior has been observed previously for polymer
blends containing P407 and other acrylic acid derivative with a
similar cross-linking degree as C974P to carry hypericin [69].
In this study, the polymeric micelle relaxation due to the hydro-
phobic drug could explain this behavior and be related to the
low yield values in the flow rheology analysis. On the other
hand, CUR did not significantly (p = 0.06597) influence the
adhesiveness values of different preparations. This phenome-
non has been observed for other polymer blends containing
hydrophobic drugs [7] since the mucoadhesive properties are
obtained by the interaction between the hydrophilic portion of
the polymeric micelles and mucosa [70].
It was also observed that an increase in temperature significant-
ly (p < 0.05) increased hardness, compressibility and adhesive-
ness due to the thermoreversilibity of the material, which favors
the structuring of the systems, as previously observed in the
flow rheology with higher consistency index numbers. These
higher values are desirable for a higher adhesion to the buccal
cavity, leading to longer contact time. These results confirm
that the system is mucoadhesive but also warrant further
mucoadhesion investigations [11,59,71].
The gel ability to flow and return to the initial state is defined as
elasticity [9]. In addition, cohesiveness is related to the restruc-
turation and molecular interactions after subsequent shear stress
during the application of the system [67,72]. The incorporation
of CUR did not significantly influence (p < 0.05) the elasticity
and cohesiveness, which could be explained by the influence by
hydrogen bonds and water mobility in the sample. As elucidat-
ed in location studies, CUR is a hydrophobic molecule that is
located in the core of polymeric micelles and thus it should not
influence this parameter [9]. Regarding the temperature effect
(at 25 and 37 °C), the preparations demonstrated elasticity and
cohesiveness values significantly lower (p < 0.05) at 37 °C.
Syringeability
The work required to expel the formulation from a syringe
(syringeability) at 25 °C was investigated by a texture analyzer.
This test was performed in order to simulate extrusion of the
formulation from the packaging material and during the admin-
istration over a lesion in the buccal cavity [59]. The effect of
CUR incorporation in this system was evaluated, and despite
the fact that the formulation containing CUR displayed a lower
syringeability (32.6383 ± 2.1814 N·mm), it was not significant-
ly lower (p > 0.05) than the syringeability of preparations with-
out CUR (34.0390 ± 1.3390 N·mm). Thus, CUR incorporation
did not influence the syringeability of the formulations and the
results indicated the ability to administer the system [59].
Mucoadhesive properties
In vitro evaluation of mucoadhesive strength by
detachment force
The mucoadhesive characteristics of preparations with and
without CUR were evaluated by detachment force using a
partially hydrated mucin disc as substrate [59,70]. According to
this method, it is possible to obtain a graph with the force re-
quired to separate two surfaces with time and the maximum re-
quired force to separate the formulation from the mucin disc
(mucoadhesive force). In addition, the adhesion work values
were calculated.
The incorporation of CUR in mucoadhesive thermoresponsive
systems led to a significant increase (p < 0.05) for both
the mucoadhesive force from 0.2109 ± 0.0054 N without
CUR to 0.2175 ± 0.0016 N with CUR and increase in the adhe-
sion work from 0.6890 ± 0.0377 N·mm without CUR to
0.7667 ± 0.0475 N·mm with it incorporated. However, these
results were not observed for adhesiveness, which could
provide evidence of adhesion. This parameter evaluates the
interaction between the formulation and polycarbonate probe,
where this lower specificity explains this result. Conversely, the
detachment force method relates the interaction of C974P-
hydroxyls and the mucin chain. This is provided by the nano-
structuring of polymer blends at body temperature, and hence, a
P407 micelle structure with a hydrophobic nucleus and hydro-
philic shell, which interacts with a mucoadhesive polymer in
the external portion of polymeric micelles [10]. Moreover, these
results are clinically relevant since the formulations containing
CUR would display a longer residence time than the systems in
the absence of this drug. Hence, the formulation should demon-
strate the intimate contact with the oral mucosa, for prolonged
periods, which could provide the concentration of the drug
close to the cancer lesions with higher bioavailability [73].
The calculation of mucoadhesive force and adhesion work has
already been discussed by other authors [70] since mucoadhe-
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Figure 9: (A) Cumulative retention profile of a polymeric system containing poloxamer 407, Carbopol 974P® and curcumin retained in a mucous layer
versus time. (B) Oral porcine mucosa after the end of the test.
sive force is the most commonly used parameter to describe
mucoadhesion. However, adhesion work seems to be influ-
enced by the elasticity and plasticity of the investigated
systems. It is suggested in the literature as the most suitable
term for the evaluation of the detachment force since it can
better detect the differences in mucoadhesive ability [74], as
was observed for the formulations with and without CUR.
Moreover, the work calculation (if converted to units of Joule)
reflects the necessary energy to separate two surfaces. Thus, the
significant increase of adhesion work correlates with higher
interaction between the mucin surface and the preparations con-
taining CUR.
Ex vivo mucoadhesive properties by falling liquid
Besides the detachment force, the determination of the mucoad-
hesive properties of nanostructured systems could also be
explored by liquid falling experiments [30,74,75]. This method
is related to the ability of systems stay adhered to surface
mucosa with the falling liquid (PBS buffer) at 4 mL/min during
20 min. Higher flow resistance evidences strong adhesive inter-
actions between preparations and mucosa. The amount of
adhered gel is calculated in an indirect method. Thus the formu-
lation eluted with buffer in a beaker containing Tween 80 and
the drug in the formulation was quantified by chromatographic
methods. Consequently, it was evaluated only for the CUR
systems. The retention of the systems without CUR have
already been evaluated by a similar method, where the formula-
tions were marked with FITC-dextran and the retention was in-
vestigated by fluorescence microscopy [70]. The cumulative
formulation percentage adhered versus time is displayed in
Figure 9.
The time buffer elution effect as a function of time over the
sample was statistically investigated and it was verified to sig-
nificantly decrease (p < 0.05) the gel retention with time.
Besides, the high variability observed is due to the irregulari-
ties of the mucosa surface. Thus, the formulation has already
been eluted completely after 5 min. Even if the methodology
used to evaluate the retention of the formulations without CUR
was different [70], it is possible to compare the results, since the
PBS flow rate used was the same (4 mL/min). In this sense, the
tests carried out by Bassi da Silva and collaborators [70]
demonstrated that the systems were eluted completely after
5 mL elution, which corresponds to 1 min 15 s. In this sense,
the systems containing CUR demonstrated improved retention
in comparison with the systems without CUR. This result
agrees with the mechanical and rheological characteristics ob-
served. One of the replicate images is showed in Figure 9B.
In vitro drug release profile
During the development of drug delivery systems for buccal ap-
plication, in vitro drug release is highly important and is consid-
ered a prerequisite for absorption as it contributes to the rate
and extension of drug bioavailability in the body [76]. More-
over, these investigations can distinguish between different
systems containing the same drug, the same formulations after
aging, and process changes during the preparation process
[17,72].
CUR release profiles were obtained by the continuous monitor-
ing of drug release over time. The key factors which could
affect CUR release are release media volume, temperature and
agitation or flow and cellulose acetate membrane [77]. Thus, in
vitro drug release of CUR from the mucoadhesive nanostruc-
tured systems was carried out with controlled temperature and
agitation in order to simulate conditions in the buccal cavity
without regard to other physiological aspects (pH, salt concen-
tration, enzymes and mouth movements during swallowing and
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Figure 10: Release profile of CUR from a mucoadhesive nanostructured system containing 15% (w/w) P407, 0.25% (w/w) C974P and 0.08% (w/w)
CUR.
speaking). These initial tests are important to verify if the drug
could be released from the drug delivery system and how the
applied technology influences the availability of the drug.
Another aspect to be considered for the in vitro drug release
analysis is the choice of release medium. For hydrophobic
drugs, sometimes it is necessary to add surfactants that can
provide the sink condition. In this study, Tween 80 was used as
a surfactant, as previously used in other in vitro CUR drug
release investigations [30,78]. Tween 80 can interfere with the
structure and rheological properties of the peripheral area of the
gel. However, this situation is similar to in vivo conditions,
where other substances with surfactant properties can be present
in buccal environment [59,79].
The complete release of CUR (100%) occurred after approxi-
mately 8 h (Figure 10), making it suitable for buccal applica-
tions. The general equation (Equation 7) described for poly-
meric systems [80] was used to evaluate the release mechanism
of CUR. Here, the release exponent (n), which determines if the
drug release mechanism is Fickian (Case I) or non-Fickian
(transport Case II, anomalous or super case II) revealed an n
value of 0.6517. The nanostructured systems displayed anom-
alous release kinetics, hence, the polymeric chains were slowly
reorganized, whereas CUR diffused by time-dependent anom-
alous effects. The solvent diffusion velocity displayed similar
relaxation of the polymeric chains [77].
Ex vivo permeation of curcumin in porcine oral
mucosa
Permeation studies are considered fundamental to determine the
viability of oral mucosa as a targeting site for drug delivery
[81,82]. These studies can be performed ex vivo, in vitro or in
vivo and are dependent of the drug physicochemical character-
istics and its behavior when incorporated in drug delivery
systems and biological target tissue. The buccal cavity presents
significant differences in permeability due to the composition
and thickening of the mucosa [81,82].
Different animal species display varying thickness and kera-
tinization patterns with porcine oral mucosa the most common-
ly employed for ex vivo testing due to the physiological similar-
ities with human tissue, ethical considerations and low cost [81-
83].
Permeation assay using a Franz cell is a quantitative technique
where the amount of drug in the receptor medium is measured
according to its physicochemical characteristics, for example,
by chromatography or spectrophotometry. Thus, the perme-
ation kinetic profile and the amount of retained drug in the
mucosa can be measured. Considering the local application, it is
advantageous for the drug to slowly permeate the mucosa with-
out reaching blood vessels and systemic circulation [8].
The cumulative permeation percentage was calculated after
each time point in porcine oral mucosa. However, even after
24 hours no drug in the receptor compartment was detected
suggesting that the amount of CUR was below the detection
limit for the chromatographic method used.
The retention of CUR in porcine oral mucosa was 6.99 ± 0.49%
(or 47.67 ± 3.33 µg/cm3), which demonstrates that the drug was
retained in the mucosa but did not reach the blood flow. These
results were influenced by the absence of the water in the donor
acceptor. This condition promoted the relation with permeation
by the PAS technique. These results were favorable for local
application over the initial stages (Stage 0 – carcinoma in situ,
Stage I – less than 2 cm tumor and Stage II – more than 2 and
less than 4 cm tumor) after surgical procedure. Additionally,
localized and initial tumors enable the choice of less aggressive
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Figure 11: Optical absorption spectra obtained from PAS with (A) CUR and polymeric systems with and without CUR, (B) permeation of CUR through
mucosa and (C) area of behavior of permeation of absorption band in 427 nm in mucosa.
treatments, such as the administration of nanostructured CUR
[26,27]. According to Sannomiya and Furukawa [84], the
surgical procedure is indicated for buccal squamous cells in
initial stages, achieving tissue without tumor margin. For more
advanced tumors, the use of chemotherapy and radiotherapy
adjuvants is recommended [84].
Photoacoustic spectroscopy is useful in the investigation of
permeation and distribution of substances in biological tissues
in vitro, ex vivo and in vivo. This technique is based on the de-
termination of optical spectral absorption by a photoacoustic
signal created by the interaction of matter with radiation of a
known wavelength [7,85]. Besides, the relatively low cost, non-
destructible manner, and ability to detect low amounts of sam-
ple are interesting for investigation of opaque samples [7].
Moreover, this is a qualitative technique that determines if a
drug can permeate or not and, if so, the depth of tissue that can
be permeated. The permeation of CUR from polymer blends
containing P407 and C974P® were performed in porcine
mucosa by photoacoustic spectroscopy and the photoacoustic
spectra of the formulations, tissues and permeation of CUR are
shown in Figure 11.
The optical absorption spectra of CUR and formulations are
presented in Figure 11A. A Gaussian adjustment was per-
formed in order to decompose the spectra into its components.
It can be observed that the drug exhibits an intense band that
varies from 250 to 700 nm, with peaks around 250, 315, 427,
515 and 659 nm. The main absorption band of CUR is located
at 427 nm and is due to the aromatic rings of hydroxyl groups
and ether [86]. The polymer blend 15/0.25 demonstrated a large
band that varies from 250 to 350 nm, with peaks at 250 to
295 nm. On the other hand, the blend 15/0.25/0.08 displays
variation from 250 to 500 nm with peaks at 250, 295, 315, 359
and 427 nm. In this sense, the detection of these characteristic
bands in the mucosa is indicative of the presence of the drug.
Regarding the photoacoustic spectra of porcine oral mucosa
(Figure 11B), all samples displayed a band at 415 nm related to
the blood vessels. Figure 9C exhibits that CUR from formula-
tions could permeate the mucosa. Moreover, the thermal
diffusion length (µs) was 31 µm on both sides of the oral
mucosa. Thus, CUR permeated the total sample thickness
(818 µm).
In this sense, the results of the PAS and Franz cell technique are
complementary, since PAS can elucidate if the drug could
permeate and the former is able to quantify the concentration of
drug that went through the receptor vessel and was retained in
the mucosa.
Drug and formulation cytotoxicity
The cytotoxicity potential of the drug and formulations with and
without CUR were investigated on squamous carcinoma cells
(FaDu and Cal27) and normal oral immortalized keratinocytes
(FNB6). The three cell lines were exposed to a wide range of
drug concentrations (0, 2.5, 5, 10, 20, 40, 80, 120 and 240 µM)
for 24 h. Moreover, another range of drug concentrations (2000,
1500, 1000, 500, 300, 100, 20, 10 µM) was utilized for the
formulations. After this period, cell viability was indirectly de-
termined by MTT metabolic assay (Figure 12).
The viability of Cal27 was significantly decreased (p < 0.05) by
the presence of the formulations, regardless of the presence of
CUR. This cytotoxic effect was not observed in the FaDu and
FNB6 cells. The cytotoxic effect of the formulations could be
explained by the presence of P407, a known surfactant. The in-
corporation of CUR into nanostructured systems caused a sig-
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Figure 12: Cytotoxicity of formulations: (A) cell survival curves of drug and formulations, (B) IC50 comparisons of drug and formulations for two SCC
(FaDu and Cal27) and one normal oral (FNB6) cell lines. Each IC50 value and percent cell survival represent average ± SEM (n = 3). CUR dispersed
in DMSO aqueous solution exhibited cytotoxicity on all three cell types with average IC50 of 24.90 ± 2.30, 7.205 ± 1.831, 15.916 ± 3.440 µM, for
FaDu, Cal27 and FNB6, respectively. The possible DMSO interference on methodology was investigated (Supporting Information File 1, Figure S2).
nificant (p < 0.05) increase in the IC50 values for both FaDu
and FNB6 compared to Cal27.
This behavior indicated that CUR could be released and
permeate before it could kill the cells. Moreover, the presence
of CUR significantly decreased the IC50 due to its cytotoxicity
properties [87]. The formulations were diluted in order to main-
tain the viability of the cells. Therefore, CUR is released into
the medium that has a large amount of organic molecules and
low water activity to disperse the drug. However, each cell line
was cultivated in a different type of medium, DMEM, RPMI
and Green’s medium for Cal27, FaDu and FNB6, respectively.
These different media could explain the results. The Cal27
viability was quite similar when treated with the drug and with
the formulations, thus the same drug concentration is likely
available. The slow drug release, ex vivo retention of CUR in
the mucosa and the cytotoxic results suggest that these formula-
tions would not be effective in primary therapy. However, it
could be very useful after surgical procedure in order to kill the
remaining cells.
Conclusion
The physicochemical, mechanical, pharmaceutical and biologi-
cal properties of mucoadhesive nanostructured systems contain-
ing CUR were explored in this study. The photophysical inter-
actions, CUR incorporation kinetics and the location of drug in
the micelles were elucidated. The pharmaceutical aspects, in-
cluding rheology, mechanical properties, CUR release and
permeation using two complementary methods were also inves-
tigated. Moreover, the biological characterization involved in-
vestigation of the cytotoxicity in tumor and healthy cell lines.
The formulations prepared from solid dispersions stored at
25 °C containing P407, C974P and CUR displayed viscoelastic
properties, plastic behavior with rheopexy at body temperature
(which provides better retention), and increased mucoadhesive
force due to the presence of CUR. CUR tends to be located in
the core of the micelles; consequently, the drug displayed slow
and complete release after 8 h but did not permeate the porcine
oral mucosa. The cytotoxicity studies revealed the increase in
the cytotoxic effects for some tumor cell lines (Cal 27) when in-
corporated into the formulation but decreased cytotoxic effects
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in healthy cells. Therefore, the nanostructured system demon-
strated promising results due to the selectivity towards cancer
cells in a monolayer cell culture in addition to exhibiting excel-
lent physicochemical properties. Hence, further activity studies
should be performed in tissue-engineered and in vivo models in
order to test the performance of these systems in a more com-
plex environment.
Experimental
Materials
Curcumin (>98% purity), poloxamer 407 and mucin from
porcine stomach type II were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Carbopol 974P® was kindly donated by
Lubrizol (São Paulo, SP, Brazil). Curcumin C3 complex® was
received from Sabinsa® (West Windsor, USA) and triethanol-
amine, used as a neutralizing agent, was purchased from Galena
(Campinas, SP, Brazil). Potassium iodide was purchased from
Biotec (São Paulo, SP, Brazil), sodium chloride was purchased
from Nuclear (Diadema, SP, Brazil) and polyssorbate 80
(Tween 80®) came from Synth® (Diadema, SP, Brazil).
Dulbecco’s Modified Eagle’s Medium high glucose (DMEM),
fetal bovine serum (FBS), ʟ-glutamine, penicillin, streptomycin
and trypsin were purchased from Sigma-Aldrich (St. Louis,
MO, USA).
Preparation of formulations
C974P (0.25%, w/w) was dispersed in purified water using a
mechanical stirrer until complete dispersion. P407 (15%, w/w)
was added to this mixture and the preparation was stored at
4 °C to ensure the complete wetting of the compounds. After
12 h, the formulations were stirred to provide the complete mix-
ture of the two polymers. The final preparation was neutralized
with triethanolamine, centrifuged at 3000 rpm to remove air
bubbles, and stored at 4 °C for at least 24 h before further anal-
ysis [1,10,11]. Regarding the nanostructured systems contain-
ing curcumin, 15% (w/w) P407 was dispersed in ethanol and
0.08% (w/w) curcumin was added to the mixture and homoge-
nized until complete mixture. The ethanol was eliminated using
a rotary evaporator at 60 °C. When a thin film was obtained, the
preparation was stored in a desiccator for 24 h. Afterwards, the
thin film was added to the dispersion containing a mucoadhe-
sive polymer (C974P), which was previously prepared. The
system was stirred and finally the pH was adjusted to 7.0 using
triethanolamine.
The nanostructured system containing CUR was also prepared
by a second method (direct addition of CUR after preparation of
binary polymeric system). Firstly, 0.25% of C974P was added
to purified water and agitated until complete dispersion. Subse-
quently, 15% P407 was added to this mixture and stored in the
refrigerator for 12 h. Afterwards, the mixture was agitated,
CUR (0.08%, w/w) was added and the system pH was adjusted
to 7 with triethanolamine.
Interaction studies of curcumin in
mucoadhesive nanostructured systems
Interaction evaluation by photophysical studies
The interaction between CUR and the polymer blend was evalu-
ated by fluorescence spectrophotometry, where the formula-
tions were diluted in water and the final concentration of the
components were 1.8 × 10−5 mol/L curcumin, 0.01% (w/w)
P407 and 0.0001675% (w/w) C974P. The behavior of the
formulations was monitored regarding the increase of tempera-
ture and pH changes in the fluorescence emission spectra and
anisotropy values obtained by the fluorescence spectropho-
tometer (Varian Agilent Technologies®). The anisotropy (r)
was automatically calculated by the software Eclipse ADL
Program Selector, according to the Equation 1:
(1)
where IVH and IVV represent the intensity measured by the exci-
tation of the vertically aligned polarizer and the horizontally
aligned polarizer, respectively. G is the instrumental correction
factor of the ratio of the sensitivities for vertically and horizon-
tally polarized light [48,88,89].
The excitation wavelength was 422 nm with emission wave-
length 440 to 700 nm and the emission slit was set to 5–10 nm.
All the systems were evaluated at 10 (below the critical micellar
temperature), 25, 37 and 45 °C (above the critical micellar tem-
perature) at pH 7. In addition, the systems containing P407 and
CUR were evaluated at pH 7 and 10 at a temperature of 37 °C.
At the same time, the binary polymeric systems were moni-
tored in pH 5, 7 and 10 at 37 °C. All the measurements were
performed after thermal equilibrium was achieved [46,90,91].
Studies of curcumin incorporation kinetics
In order to simulate the mechanism of incorporation of
curcumin and the required time for the drug to reach the core of
the polymeric micelles, the incorporation kinetic profile was de-
termined using the CUR addition sequence based on the second
method of preparation. In a quartz cuvette, 22 µL of CUR stock
solution (4.8 × 10−3 mol/L) was added to the P407 and C974P
polymeric dispersion without pH adjustment, totaling 3 mL.
The final concentration was 3.6 × 10−5 mol/L CUR, 0.02%
(w/w) P407 and 0.0032% (w/w) C974P. The kinetic profile was
evaluated at 25 °C and 37 °C, over 125 min by monitoring the
fluorescence emission spectra, where the excitation wavelength
was 422 nm and the emission slit was set to 5–10 nm [92].
Beilstein J. Nanotechnol. 2019, 10, 2304–2328.
2321
Localization of curcumin in nanostructured systems
The relative location of curcumin in the polymer blends con-
taining P407, C974P and CUR prepared by solid dispersion
stored at 25 °C and 5 °C was performed using iodide (I−) as a
hydrophilic suppressor. Firstly, 133 µL of gel containing
CUR and purified water were added to a 100 mL volumetric
flask. Subsequently, increasing aliquots of KI (1 mol/L) were
added in a solution containing polymeric micelles of CUR
(3.6 × 10−5 mol/L), 0.02% (w/w) P407, and 0.0032% (w/w)
C974P. The spectral emission profile from 440 to 700 nm was
monitored after each iodide addition using an excitation wave-
length of 422 nm and in most cases the emission slit was set to
5–10 nm. The Stern–Volmer (Ksv) constant was obtained at 25
and 37 °C by Equation 2:
(2)
where the emission values in the presence and absence of a
suppressor are represented by F0 and F, respectively, and the
concentration of iodide in the solution is given by [I−]
[91,93,94]. The dilution effect promoted by the addition of each
hydrophilic suppressor aliquot was corrected for each spectral
emission profile.
Morphological analysis by scanning electron
microscopy
The morphological characteristics of formulations in the pres-
ence and absence of curcumin were evaluated by an electron
scanning microscope (Quanta FEI, Thermo®, Oregon, USA).
Approximately 2 g of the formulation was freeze-dried and a
sample of material was placed on double-sided tape, and the
sample was coated with colloidal gold under argon atmosphere.
Morphological analysis by transmittance electron
microscopy
The morphology of the formulations was also determined using
a JOEL JEM 1400 transmission electron microscope (Peabody,
MA, USA). 0.2 mL of the nanostructured material was diluted
in a 10 mL volumetric flask and placed on a formvar/Carbon
200 mesh, copper grid (Ted Tella, Redding, CA, USA). This set
was negatively stained with 2% (w/v) uranyl acetate solution
for observation [57,95,96]. The samples were prepared at 37 °C.
Micelle size analysis
The hydrodynamic diameter (D), polydispersity index (PDI)
and size distribution of 10%, 50% and 90% (D10%, D50% and
D90%) of micelles of the nanostructured systems was carried
out by dynamic light scattering (DLS) analysis using a
NanoPlus Particle Size Analyzer (Particulate Systems,
Norcross, GA, USA). The formulation samples were diluted 50
and 10 times to provide P407 concentrations of 0.3% and 1.5%
(w/w), respectively. The measurements were performed at
25 °C and 37 °C with at least three replicates.
Rheometry
The rheological analysis of the formulations was determined
using a controlled stress rheometer (MARSII, Haake Thermo
Fisher Scientific Inc., Newington, Germany) at 25 °C and
37 ± 0.1 °C with a geometry employing a parallel steel cone-
plate (35 mm diameter, separated by a fixed distance of
0.052 mm, where the cone angle is 2°), as shown in Figure 13.
The samples were carefully placed in the device, and it was
allowed to equilibrate for at least 1 min before analysis to
ensure the minimized shearing of the sample.
Continuous shear flow rheology
In flow mode, the downward and upward curves were obtained
over shear rates from 0 to 2000 s−1, increasing over a period of
150 s, retained at the high limit during 10 s, and then decreas-
ing over a period of 150 s. The flow properties were deter-
mined from at least five replicates and the upward flow curves
were modelled using the power-law fluid (or the Ostwald–de
Waele) relationship (Equation 3) [28,31,47]:
(3)
where τ is shear stress (Pa), K is the consistency index [(Pa·s)n],
γ̇ is shear rate (s−1), and n is the flow behavior index (dimen-
sionless).
The yield stress was evaluated by the rheological models of
Casson (Equation 4) and Herschel–Bulkley (Equation 5) [97]:
(4)
(5)
where τo is yield stress (Pa) and ηp is the Casson plastic
viscosity. Moreover, the hysteresis area was calculated by the
software RheoWin 4.10.0000 (Haake®).
Oscillatory rheology
In oscillatory mode, the linear viscoelastic region (LVR) was
determined for each binary polymeric system. Subsequently, the
frequency sweep analysis was performed from 0.1 to 10.0 Hz at
25 and 37 °C. The viscoelastic properties of the preparations,
storage modulus (G’), loss modulus (G”), dynamic viscosity
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Figure 13: Schematic presentation of the rheological analysis setup utilized for continuous shear (flow) and oscillatory rheometry analysis of the
formulations.
(η’) and the loss tangent (tan δ) were calculated using the soft-
ware RheoWin 4.10.0000 (Haake®). The analyses were per-
formed at least in five replicate samples [27,28,98,99].
Sol–gel transition temperature
In oscillatory mode with a controlled temperature ramp, the
sol–gel transition temperature (Tsol–gel) of the formulations was
investigated as well. The LVR of each system was performed at
5 °C and 60 °C. Afterwards, over a range of 5–60 °C, the tem-
perature sweep analysis was performed at a defined frequency
(1.0 Hz) with a heating rate of 10 °C/min with controlled stress.
The viscoelastic properties, G’, G”, η’ and tan δ were calcu-
lated using the software RheoWin 4.10.0000 (Haake®) with at
least five replicate samples in each case. Tsol–gel is defined as
the temperature at which G’ was halfway between the values
for solution and gel and was calculated for all preparations
where η’ increased with the significant increase of temperature
[47,49-51].
Texture profile analysis
The texture profile analysis (TPA) of preparations with and
without CUR was carried out using a texture profile analyzer
TA-XTplus (Stable Micro Systems®, Surrey, UK) at 25 and
37 °C, in TPA mode, for at least three replicates [59]. A 13 g
formulation was compressed at a depth of 15 mm, two times, by
an analytical probe of polycarbonate (10 mm diameter) at a
speed of 2 mm/s and with 15 s between the first and the begin-
ning of the second compression. The resultant force versus dis-
tance plot provided the texture parameters, hardness, compress-
ibility, adhesiveness, elasticity and cohesiveness [59].
Mucoadhesive properties
In vitro evaluation of mucoadhesive strength by
detachment force
The mucoadhesive properties of the formulations (with and
without CUR) were investigated using a texture analyser (TA-
XTplus, Stable Micro Systems®) in tension mode at 37 °C,
repeated at least three times. Firstly, the mucin disc was pre-
pared by the compression of crude mucin, hydrated in mucin
solution 5% (w/w) for 30 s and fixed in the TPA probe. The
excess liquid was gently removed with absorbent paper. The
samples were placed behind the analytical probe, which was
lowered until both surfaces were in contact. Subsequently, a
force of 0.1 N was applied for 30 s in order to ensure the inti-
mate contact between the mucin disc and sample. Afterwards,
the probe was raised at speed of 1.0 mm/s and the force re-
quired to detach the mucin disc from the formulations was de-
termined from the plot of force versus time.
Ex vivo analysis of mucoadhesive properties by
falling liquid method
The mucoadhesive properties of the formulations were also in-
vestigated by an ex vivo methodology using porcine oral
mucosa on a flow through method. Porcine oral mucosa was
taken from the cheek of young, white and freshly slaughtered
pigs from a slaughterhouse authorized for human consumption
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Figure 14: Schematic presentation of the setup utilized for ex vivo liquid falling mucoadhesion tests.
by the Brazilian Agriculture Ministry. After the oral mucosa
was excised with scissors and a surgical scalpel, the samples
were stored at −18 °C in a PBS solution and defrosted at room
temperature on the experimental day (48 hours after the oral
mucosa preparation) [30].
Inside a temperature-controlled chamber (37 °C), the oral
mucosa samples were placed on the test channel behind a
syringe-pump system, where phosphate sodium buffer was
dropped over the mucosal samples (flow of 4 mL/min)
(Figure 14). 100 µL of the formulation was placed over the oral
mucosa and kept warm, in order to allow the adhesion between
the mucosa and formulation. After 5 min, PBS was flowed over
the set for 20 min. The samples of the elution liquid were
collected after 1, 2, 5, 10, 15 and 20 min, with 1% (v/v)
Tween 80 to allow the complete dispersion of CUR. The sam-
ples were diluted with methanol (1:2) and analyzed by the
HPLC method. 20 µL of the sample was injected into a
Shimadzu LC CBM 20 system (Tokyo, Japan) equipped with a
UV–vis detector (SPD 20 A) and manual injector (7725i). A
C18 reversed phase column (5 µm × 4.6 mm × 250 mm, Luna
PFP, Phenomenex®, Torrance, USA) was used as a stationary
phase and the mobile phase was acetonitrile and acetic acid
solution (1.5%, v/v) in a gradient elution. The flow was
adjusted to 1.0 mL/min and the peak area was detected at 425
nm. The amount of formulation removed from the surface of the
substrate was calculated and deducted from the total, providing
the retention data. The analysis was performed in triplicate
using new oral mucosa for each experimental essay [10,52,53].
Syringeability determination
The formulation resistance to compression inside a syringe was
determined by the syringeability work. The investigations were
performed in a texture analyzer (TA-XTplus) in compression
mode [100]. In order to avoid the entrapment of air, the formu-
lations were carefully packed in 1 mL plastic syringes at
30 mm. Each syringe was vertically fixed in the texture meter
and pressed at 2.0 mm·s−1, to a depth of 30 mm, until initial
contact with the syringe plunger was made. The analysis was
performed at 25 °C with at least three replicates [47,55]. During
the compression of the plunger, a graph of force versus dis-
tance was derived and the work demonstrates the resistance of
the compression of syringe content.
In vitro drug release
The kinetics of the release of curcumin from the binary poly-
meric system was carried out using double-wall glass beaker
with water bath temperature control at 37 ± 0.5 °C. 1.0 g poly-
meric system was placed on the bottom of the vessel at 37 °C to
ensure the complete gelation of the formulation. Subsequently,
16 mL of the release media (Tween 80 aqueous solution; 1%,
v/v) was carefully added in the recipient to obtain sink condi-
tions and kept under constant agitation (Figure 15) [11,56,101].
500 µL aliquots of samples were collected and replaced with
the same volume of fresh medium at fixed time intervals, 0.5 h,
1 h, 2 h, 3 h, 4 h, 6 h, 8 h and 24 h. These samples were diluted
with methanol (1:2), filtered with PTFE membranes and quanti-
fied by the HPLC method, as previously described [30]. The
release profiles were calculated by plotting the amount released
versus time. These release profiles were fitted with the
Korsmeyer–Peppas equation (Equation 6), which describes the
drug release from matrix polymeric systems [102]:
(6)
where F represents the fraction of the drug released, t is the
time released, k is the combined kinetic constant of structural
and geometric characteristics of the apparatus and n is the
release exponent, which reveals the drug release mechanism.
Ex vivo analysis of curcumin permeation in
oral mucosa
Mucosa permeation by Franz cells
The permeation was investigated using porcine oral mucosa ob-
tained as previously described in the section on ex vivo analy-
sis of mucoadhesive properties by falling liquid method. Firstly,
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Figure 15: Schematic presentation of the modified Franz’s cell used for the in vitro curcumin release measurements from the nanostructured system.
the tissues were defrosted at room temperature, then cut and
placed between the donor and receptor compartment of the
Franz cell. The receptor media, composed of 1% (v/v)
Tween 80 in PBS buffer (pH 7.4), which provided the
solublization of CUR, was placed in the receptor compartment.
This system was maintained at 37 °C at constant stirring. 1 mL
of the formulation was placed homogeneously over the mucosa
in the donor compartment. The temperature of the formulation
was maintained at 37 °C by thermal exchange between the
tissue and the formulation and also the temperature control pro-
vided by the equipment [103,104]. Afterwards, 500 µL of the
receptor medium was collected and replaced by fresh medium
to ensure sink condition at 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h and
24 h. The samples were diluted in methanol (1:2), filtered in
PTFE and quantified by the HPLC method. At least three repli-
cates were performed [56,61].
For the retention of CUR in the tissue, the porcine mucosa was
taken from the recipient. The tissue was cut into small pieces
and placed in a 5 mL volumetric flask with methanol and soni-
cated for 15 min. Subsequently, the 5 mL volumetric flask was
completed, filtered with PTFE and quantified using the HPLC
method. The analysis was performed for at least three samples.
Mucosal permeation by photoacoustic spectroscopy
The permeation of curcumin from the mucoadhesive thermore-
sponsive systems, performed in porcine oral mucosa, was inves-
tigated by photoacoustic spectroscopy. The oral mucosa was
taken from porcine cheek as described previously. Firstly, 30 µg
of the formulation was homogeneously placed over a 1 cm3 sur-
face of the oral mucosa. After 30 min, the sample was evalu-
ated by photoacoustic spectroscopy. This essay was performed
on home-built experimental equipment composed of a 1000 W
Xenon arc lamp (Oriel, model 68820) as the light source with a
nominal power of 800 W. The light was diffracted when
passing through the 3.16 mm input and output slits of the mono-
chromator (Oriel, model 77250) and then modulated at 13 Hz
with a mechanical chopper (Stanford Research Systems, model
SR 540) and then focused on the sample. Band-pass filters were
used to eliminate higher order diffraction. The sample was
placed inside the photoacoustic cell and sealed with a trans-
parent quartz window (diameter of 8 mm and thickness of
2 mm). The photoacoustic signal generated by pressure changes
resulting from the periodic heating of the sample was collected
by a capacitive microphone (Brüel and Klaer, model 2669). A
lock-in amplifier by EG&G Instruments, model 5110, was used.
The thermal diffusion length (µs) was used to calculate the
depth of tissue that contributed to the photoacoustic signal:
(7)
where D is the sample thermal diffusivity (cm−2·s−1) and f is the
light modulation frequency (Hz). Considering the thermal diffu-
sivity of mucosa equal to skin, due to the similarity overall in
terms of molecule distribution and histological architecture
[105], D = 4.1 × 10−4 cm2·s−1 [106,107] and f =13 Hz. Conse-
quently, µs was 31 µm for oral mucosa and the total sample
thickness was constant around 818 µm.
The photoacoustic signal was interpreted from the band absorp-
tion spectra, since the final photoacoustic signal is proportional
to the sample absorption coefficient [107]. All spectra were
normalized with a sample of carbon black in order to correct the
source emission intensity in each wavelength [108].
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Moreover, the spectra of at least three porcine oral mucosa were
obtained by placing the tissue inside the photoacoustic cell and
illuminating the side to be measured; then the tissue was turned
upside down to illuminate the opposite side [56,60].
Cell culture
The cell lines FaDu (LGC Promochem, Middlesex, UK), origi-
nally isolated from a hypopharyngeal tumor and Cal27 (ATCC,
Manassas, VA, USA, CRL-2095) from tongue squamous cell
carcinoma (ECACC, Health Protection Agency Culture Collec-
tions, Salisbury, UK) were used in this study. FaDu cells were
cultured in RPMI-1640, whereas Cal27 was cultured in
Dulbecco’s modified Eagle’s (DMEM) medium high glucose.
Both media were supplemented with 10% (v/v) fetal bovine
serum (FBS), 2 mM ʟ-glutamine, 100 UI/mL penicillin and
100 µg/mL streptomycin. The immortalized cell line FNB6 (a
kind gift from Professor Keith Hunter), originally isolated from
normal oral keratinocytes, were cultured in adenine enriched
medium; DMEM and Ham’s F12 medium in a 3:1 (v/v) supple-
mented with 10% (v/v) FBS, 0.1 mM cholera toxin, 10 ng/mL
epidermal growing factor, 0.4 µg/mL hydrocortisone, 0.18 mM
adenine, 5 mg/mL transferrin, 2 mM ʟ-glutamine, 0.2 mM
triiodothyronine, 0.625 mg/mL amphotericin B, 100 UI/mL
penicillin and 100 µg/mL streptomycin. All cells were incubat-
ed at 37 °C in a 5% CO2 humidified atmosphere and sub-culti-
vated using trypsin-EDTA when 80% confluence was reached.
Cytotoxicity and biological activity evaluation
The in vitro cytotoxicity of preparations with and without CUR,
as well as the drug alone, were carried out on FNB6, Cal27 and
FaDu cells using an MTT assay as previously described [85].
Briefly, 2 × 105 cells were seeded in each well of a 96-well
plate before addition of the formulations with and without CUR
with increased polymeric content (2000, 1500, 1000, 500, 300,
100, 20, 10 µM CUR) and free CUR (240,120, 80, 40, 20, 10, 5
and 2.5 µM). After 24 h, the media with CUR and/or the formu-
lations was aspirated, the cells were washed three times with
PBS and more 200 µL media was added to each well and the
cells were incubated for a further 24 h. Monolayer cultures were
incubated for 1 h at 37 °C with 0.5 mg/mL MTT solution, after
which the solution removed and acidified isopropanol was
added to remove the blue formazan crystals. The optical densi-
ty was measured at 570 nm with a 630 nm reference correction.
Statistical analysis
The effect of CUR presence and temperature in micelle size
analysis, consistency index (K), flow index (n), yield value,
hysteresis area and texture profile analysis parameters (hard-
ness, compressibility, adhesiveness, elasticity and cohesiveness)
were statistically compared using two-way ANOVA. On the
other hand, the effect of the presence of CUR on the mucoadhe-
sive strength, softness and syringeability were statistically eval-
uated by one-way ANOVA. Moreover, the effect of the drug
and formulation on cell viability was evaluated by two-way
ANOVA. Student t-test was used to determine the influence of
temperature on dynamic viscosity of the formulations. All the
cases of ANOVA post hoc comparison of individual groups
were carried out using Tukey. For all cases, p < 0.05 was
accepted as significant [23,28,31].
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